ICTCAR014 / Innovative Cellular Therapeutics - LARVOL DELTA

Innovative Cellular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) - "'We appreciate the opportunity to present and discuss the recent clinical data achieved with our in-house developed, proprietary CoupledCAR® solid tumor CAR-T platform technology. We achieved a 60% Overall Response Rate (ORR) and a 20% Complete Remission (CR) rate in seven colorectal and three thyroid cancer patients. CR was achieved in both indications in ongoing human proof-of-concept trials being conducted across multiple hospital sites in China...We are already in pre-IND discussions with the FDA to advance our CoupledCAR® solid tumor CAR-T therapies into the clinic in the United States in the near future.'....ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014, after having received FDA IND clearance in late 2019."

Clinical data • New trial • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Innovative Cellular Therapeutics to Present New Clinical Data with CoupledCAR CAR-T in Colon Cancer at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020 (GlobeNewswire) - "Innovative Cellular Therapeutics...announced that it will present new clinical data at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020...'We have seen a 71% Overall Response Rate with 14% Complete Response in seven metastatic colon cancer patients treated in proof-of-concept trials in China with CoupledCAR^®, ICT’s novel, in-house developed, proprietary CAR-T platform technology for solid tumors'...ICT is initiating its first U.S. clinical trial with its most advanced program, ICTCAR014....ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients."

Clinical data • New trial • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Innovative Cellular Therapeutics secures equity financing to advance its next generation liquid and solid tumor CAR-T programs (GlobeNewswire) - "Innovative Cellular Therapeutics...announced that it has closed a U.S. dollar Series B+ equity financing for an undisclosed amount....Proceeds from the capital raise will be used to advance ICTCAR014 – ICT’s next generation CD19-targeting armored CAR-T cell therapy that expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells – into a U.S. clinical trial in the first part of 2020, and to further develop ICT’s 'CoupledCAR' CAR-T cell therapy platform in solid tumors."

CAR T-Cell Therapy • Financing • New trial

FDA grants IND application clearance to ICTCAR014 for r/r non-Hodgkin lymphoma (Targeted Oncology) - "An Investigational New Drug (IND) application for chimeric antigen receptor (CAR)-T cell agent, ICTCAR014, has been cleared by the FDA for treatment of patients with relapsed/refractory non-Hodgkin lymphoma, including those with PD-L1-positive tumors, according to a press release from Innovative Cellular Therapeutics (ICT)."

IND